155 related articles for article (PubMed ID: 36129951)
21. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
22. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
Kim SJ; Cho YJ; Lee DW
Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS).
Chen CH; Elsalmawy AH; Ish-Shalom S; Lim SJ; AlAli NS; Cunha-Borges JL; Yang H; Casas N; Altan L; Belaya Z; Marin F; Moll T; Gurbuz S; Brnabic A; Pavo I; Florez S
Calcif Tissue Int; 2022 Jan; 110(1):74-86. PubMed ID: 34415388
[TBL] [Abstract][Full Text] [Related]
24. Determinants of adherence to osteoporosis treatment in clinical practice.
Rossini M; Bianchi G; Di Munno O; Giannini S; Minisola S; Sinigaglia L; Adami S;
Osteoporos Int; 2006; 17(6):914-21. PubMed ID: 16538553
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of Latinas in Puerto Rico and the US mainland receiving teriparatide in the DANCE observational study.
Ruff VA; Acosta A; Soto-Raices O; Sierra-Zorita R; Toro-Torres R; Rodríguez-Ginorio H; Comulada A; Chiang AY; Krohn K; Taylor KA;
P R Health Sci J; 2014 Sep; 33(3):105-11. PubMed ID: 25244878
[TBL] [Abstract][Full Text] [Related]
26. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
[TBL] [Abstract][Full Text] [Related]
27. Long-term persistence with anti-osteoporosis drugs after fracture.
Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
[TBL] [Abstract][Full Text] [Related]
28. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
[TBL] [Abstract][Full Text] [Related]
29. Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service.
Delbar A; Pflimlin A; Delabrière I; Ternynck C; Chantelot C; Puisieux F; Cortet B; Paccou J
Bone; 2021 Mar; 144():115838. PubMed ID: 33385615
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
[TBL] [Abstract][Full Text] [Related]
31. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
[TBL] [Abstract][Full Text] [Related]
32. Post-fracture prescribed calcium and vitamin D supplements alone or, in females, with concomitant anti-osteoporotic drugs is associated with lower mortality in elderly hip fracture patients: a prospective analysis.
Nurmi-Lüthje I; Lüthje P; Kaukonen JP; Kataja M; Kuurne S; Naboulsi H; Karjalainen K
Drugs Aging; 2009; 26(5):409-21. PubMed ID: 19552493
[TBL] [Abstract][Full Text] [Related]
33. Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review.
Fujiwara S; Miyauchi A; Hamaya E; Nicholls RJ; Weston A; Baidya S; Pinto L; Barron R; Takada J
Arch Osteoporos; 2018 Mar; 13(1):34. PubMed ID: 29564555
[TBL] [Abstract][Full Text] [Related]
34. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.
Carbonell-Abella C; Pages-Castella A; Javaid MK; Nogues X; Farmer AJ; Cooper C; Diez-Perez A; Prieto-Alhambra D
Calcif Tissue Int; 2015 Dec; 97(6):535-41. PubMed ID: 26202819
[TBL] [Abstract][Full Text] [Related]
35. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study.
Wong M; Wan X; Ruff V; Krohn K; Taylor K
Osteoporos Int; 2012 Apr; 23(4):1445-52. PubMed ID: 21769662
[TBL] [Abstract][Full Text] [Related]
36. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better?
Kristensen PK; Ehrenstein V; Shetty N; Pedersen AB
Osteoporos Int; 2019 Sep; 30(9):1817-1825. PubMed ID: 31263921
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of osteoporosis: fracture risks, medication and treatment.
Liu W; Yang LH; Kong XC; An LK; Wang R
Minerva Med; 2015 Aug; 106(4):203-14. PubMed ID: 26125152
[TBL] [Abstract][Full Text] [Related]
38. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
[TBL] [Abstract][Full Text] [Related]
39. Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital's fracture liaison service between January 2010 and December 2011.
Dehamchia-Rehailia N; Ursu D; Henry-Desailly I; Fardellone P; Paccou J
Osteoporos Int; 2014 Oct; 25(10):2409-16. PubMed ID: 24980182
[TBL] [Abstract][Full Text] [Related]
40. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
